CA2321186A1 - Apoptosis inducing molecule ii and methods of use - Google Patents

Apoptosis inducing molecule ii and methods of use Download PDF

Info

Publication number
CA2321186A1
CA2321186A1 CA002321186A CA2321186A CA2321186A1 CA 2321186 A1 CA2321186 A1 CA 2321186A1 CA 002321186 A CA002321186 A CA 002321186A CA 2321186 A CA2321186 A CA 2321186A CA 2321186 A1 CA2321186 A1 CA 2321186A1
Authority
CA
Canada
Prior art keywords
aim
polypeptide
amino acid
cells
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002321186A
Other languages
English (en)
French (fr)
Inventor
Reinhard Ebner
Guo-Liang Yu
Steven M. Ruben
Jun Zhang
Stephen Ullrich
Yifan Zhai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/027,287 external-priority patent/US6479254B2/en
Application filed by Individual filed Critical Individual
Publication of CA2321186A1 publication Critical patent/CA2321186A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA002321186A 1998-02-20 1999-02-19 Apoptosis inducing molecule ii and methods of use Abandoned CA2321186A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US7540998P 1998-02-20 1998-02-20
US60/075,409 1998-02-20
US09/027,287 1998-02-20
US09/027,287 US6479254B2 (en) 1996-03-22 1998-02-20 Apoptosis inducing molecule II
PCT/US1999/003703 WO1999042584A1 (en) 1998-02-20 1999-02-19 Apoptosis inducing molecule ii and methods of use

Publications (1)

Publication Number Publication Date
CA2321186A1 true CA2321186A1 (en) 1999-08-26

Family

ID=26702277

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002321186A Abandoned CA2321186A1 (en) 1998-02-20 1999-02-19 Apoptosis inducing molecule ii and methods of use

Country Status (5)

Country Link
EP (1) EP1054968A1 (enExample)
JP (1) JP2002504333A (enExample)
AU (1) AU2972199A (enExample)
CA (1) CA2321186A1 (enExample)
WO (1) WO1999042584A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7964190B2 (en) 1996-03-22 2011-06-21 Human Genome Sciences, Inc. Methods and compositions for decreasing T-cell activity
US6635743B1 (en) 1996-03-22 2003-10-21 Human Genome Sciences, Inc. Apoptosis inducing molecule II and methods of use
US6495520B2 (en) 1996-03-22 2002-12-17 Human Genome Sciences, Inc. Apoptosis Inducing Molecule II and methods of use
US6479254B2 (en) 1996-03-22 2002-11-12 Human Genome Sciences, Inc. Apoptosis inducing molecule II
US6998108B1 (en) 1997-07-07 2006-02-14 La Jolla Institute For Allergy And Immunology Antibodies to p30 polypeptides and methods making and using same
US7118742B2 (en) 1997-07-07 2006-10-10 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
US6140467A (en) * 1997-07-07 2000-10-31 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
WO2000053223A1 (en) * 1999-03-11 2000-09-14 Human Genome Sciences, Inc. Apoptosis inducing molecule ii and methods of use
WO2001079496A2 (en) * 2000-03-13 2001-10-25 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
DE60143231D1 (de) * 2000-04-12 2010-11-18 Jolla Inst Allergy Immunolog Ligand des zelleintritt-vermittelnden Proteins von Herpes Simplex und Methoden zu dessen Verwendungen
US20040058367A1 (en) * 2001-02-23 2004-03-25 Hideki Matsui Casoase 3 inhibitors
WO2002066049A1 (fr) * 2001-02-23 2002-08-29 Takeda Chemical Industries, Ltd. Agents pour changement plasmique
CA2661782C (en) 2006-08-28 2019-04-16 La Jolla Institute For Allergy And Immunology Antagonistic human light-specific human monoclonal antibodies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100497017B1 (ko) * 1996-03-22 2005-11-29 휴먼 게놈 사이언시즈, 인코포레이티드 고사유도분자ii
CA2260767A1 (en) * 1996-07-19 1998-01-29 Takeda Chemical Industries, Ltd. Fas ligand-like protein, its production and use
US6346388B1 (en) * 1997-08-13 2002-02-12 Smithkline Beecham Corporation Method of identifying agonist and antagonists for tumor necrosis related receptors TR1 and TR2
WO1999011662A1 (en) * 1997-09-05 1999-03-11 Millennium Biotherapeutics, Inc. Novel molecules of the tnfr-ligand-related protein family and uses thereof

Also Published As

Publication number Publication date
WO1999042584A1 (en) 1999-08-26
WO1999042584A9 (en) 1999-11-18
JP2002504333A (ja) 2002-02-12
EP1054968A1 (en) 2000-11-29
AU2972199A (en) 1999-09-06

Similar Documents

Publication Publication Date Title
KR100497017B1 (ko) 고사유도분자ii
AU768475B2 (en) Interleukin 17-like receptor protein
US6479254B2 (en) Apoptosis inducing molecule II
JP2008081503A (ja) 死ドメイン含有レセプター５
JPH10509030A (ja) 腫瘍壊死因子−γ
CA2292835A1 (en) Ntn-2 member of tnf ligand family
JP2001501453A (ja) ヒト腫瘍壊死因子δおよびε
CA2292790A1 (en) Human tumor necrosis factor receptor tr10
CA2211003A1 (en) Human tumor necrosis factor receptor
EP1032672A1 (en) Dna19355 polypeptide, a tumor necrosis factor homolog
CA2321186A1 (en) Apoptosis inducing molecule ii and methods of use
CA2367315A1 (en) Apoptosis inducing molecule ii and methods of use
JP2001509663A (ja) ヒト腫瘍壊死因子レセプター様遺伝子
US20030166097A1 (en) Human tumor necrosis factor receptor
US6495520B2 (en) Apoptosis Inducing Molecule II and methods of use
US6130061A (en) Human stem cell antigen 2
AU771013B2 (en) Apoptosis inducing molecule II
AU734384B2 (en) Apoptosis inducing molecule II
US20040047864A1 (en) Apoptosis inducing molecule I
US8110659B1 (en) Human tumor necrosis factor receptor-like genes
AU2004202460A1 (en) Apoptosis Inducing Molecule II
JPH11503007A (ja) ヒト腫瘍壊死因子受容体
EP1114142A1 (en) Interleukin 17-like receptor protein
JPH11507208A (ja) アポトーシス遺伝子１のヒトインヒビター

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued